Extended Data Fig. 4: Change in ctDNA levels from baseline is predictive of clinical outcome to vaccine (n = 13). | Nature Medicine

Extended Data Fig. 4: Change in ctDNA levels from baseline is predictive of clinical outcome to vaccine (n = 13).

From: Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

Extended Data Fig. 4

a, Percent change in ctDNA at weeks 3 and 9 relative to baseline levels in patients with disease control (CR/PR/SD, n = 8) vs patients with progressive disease (PD, n = 5). Each circle indicates an individual patient per group. Data are presented as mean ± SEM. All P-values were evaluated by a two-tailed, Mann-Whitney test, and P-values below 0.05 were considered statistically significant. b, Percent change in ctDNA (molecular response) at Week 9 relative to baseline levels shown as best overall response evaluated by RECIST 1.1. c, Change in target lesion from baseline (%) evaluated by RECIST 1.1 in two patients who had a deeper molecular response at 95% and 100% reduction in ctDNA relative to their objective response. d, Probability of survival in patients with (n = 5) or without (n = 8) reduction in ctDNA at week 9. Significance was evaluated by the Log-rank (Mantel-Cox) test.

Back to article page